Pozaniklin

Из Википедије, слободне енциклопедије
Pozaniklin
ABT-089.png
IUPAC ime
2-metil-3-([(2S)-pirolidin-2-il]metoksi)piridin
Identifikatori
CAS broj 161417-03-4 ДаY
ATC kod None
PubChem CID 178052
UNII CL2002R563 ДаY
Hemijski podaci
Formula C11H16N2O
Molarna masa 192,258
  (verify)

Pozaniklin (ABT-089) je lek koji je razvilo preduzeće Abbott. On je parcijalni agonist neuronskih nikotinskih acetilholinskih receptora. Pozaniklin je selektivan za podtove α4β2 i α6β2.[1][2] Ovaj ligand ima nootropna i neuroprotektivna svojstva.[3][4][5] Životinjske studije sugerišu da on može da bude koristan u lečenju ADHD.[6]

Reference[уреди]

  1. Marks MJ, Wageman CR, Grady SR, Gopalakrishnan M, Briggs CA (2009). „Selectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain”. Biochemical Pharmacology. 78 (7): 795—802. doi:10.1016/j.bcp.2009.05.022. PMC 2772152Слободан приступ. PMID 19481067. 
  2. Anderson DJ, Malysz J, Grønlien JH, El Kouhen R, Håkerud M, Wetterstrand C, Briggs CA, Gopalakrishnan M (2009). „Stimulation of dopamine release by nicotinic acetylcholine receptor ligands in rat brain slices correlates with the profile of high, but not low, sensitivity alpha4beta2 subunit combination”. Biochemical Pharmacology. 78 (7): 844—51. doi:10.1016/j.bcp.2009.06.024. PMID 19555668. 
  3. Lin NH, Gunn DE, Ryther KB, Garvey DS, Donnelly-Roberts DL, Decker MW, Brioni JD, Buckley MJ, Rodrigues AD, Marsh KG, Anderson DJ, Buccafusco JJ, Prendergast MA, Sullivan JP, Williams M, Arneric SP, Holladay MW. Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties. Journal of Medicinal Chemistry. 1997 Jan 31;40(3):385-90. PMID 9022806
  4. Sullivan JP, Donnelly-Roberts D, Briggs CA, Anderson DJ, Gopalakrishnan M, Xue IC, Piattoni-Kaplan M, Molinari E, Campbell JE, McKenna DG, Gunn DE, Lin NH, Ryther KB, He Y, Holladay MW, Wonnacott S, Williams M, Arneric SP. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. Journal of Pharmacology and Experimental Therapeutics. 1997 Oct;283(1):235-46. PMID 9336329
  5. Decker MW, Bannon AW, Curzon P, Gunther KL, Brioni JD, Holladay MW, Lin NH, Li Y, Daanen JF, Buccafusco JJ, Prendergast MA, Jackson WJ, Arneric SP. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys. Journal of Pharmacology and Experimental Therapeutics. 1997 Oct;283(1):247-58. PMID 9336330
  6. Prendergast MA, Jackson WJ, Terry AV Jr, Decker MW, Arneric SP, Buccafusco JJ. Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys. Psychopharmacology (Berlin). 1998 Mar;136(1):50-8. PMID 9537682

Spoljašnje veze[уреди]